QurAlis to Present Data That Show its Splice-Switching ASOs Restore UNC13A Function in ALS and Frontotemporal Dementia
SV investment has resulted in the approval of 24 novel therapeutics
SV Health Investors bolsters senior biotech team - appoints Nikola Trbovic as Managing Partner and hires Jamil Beg as Partner
Hightop Health adds industry veteran to Board of Directors - Seasoned CEO and McLean Hospital Board Chair joins Hightop’s executive leadership
Merck to Acquire Caraway Therapeutics, Inc.
EyeBio Announces Expansion of Series A to $130 Million, Advances Development of Restoret for Retinal Diseases
SV Health Investors partners with HIT Executives Dave Dyell and Marc Hirshfield to Lead Recapitalization of Innovative Consulting Group
- 22 June 2021Portfolio NewsImbria Pharmaceuticals Announces enrolment of the first 10 patients in IMPROVE-DiCE, an Exploratory Phase 2 Study Investigating the impact of IMB-1018972 on Cardiac Energetics, Metabolism and Function in Patients with Type 2 Diabetes
- 22 June 2021Portfolio NewsAlchemab Therapeutics Appoints Douglas A. Treco, PhD as Chief Executive Officer
- 12 June 2021SV NewsKate Bingham is recognised in this year's Queen’s Birthday Honours List
- 27 May 2021Portfolio NewsPulmocide Raises $92 million in a Series C Financing to Fund Registration Program for PC945
- 18 May 2021Portfolio NewsMestag Therapeutics announces collaboration with Janssen, focused on the discovery of novel fibroblast targets for the treatment of inflammatory disease
- 17 May 2021Portfolio NewsImbria Pharmaceuticals Presents Phase 1 and Preclinical Data of IMB-1018972 (IMB-101), an Investigational Cardiac Mitotrope , at the American College of Cardiology 70th Annual Scientific Session & Expo
- 12 May 2021Portfolio NewsXilio Therapeutics Presents Preclinical Tumor-Selective Activity and Tolerability Data for XTX101 at Frontiers in Cancer Immunotherapy Virtual Symposium
- 10 May 2021Portfolio NewsTherini Bio Secures $17 Million Investment to Advance Fibrin Therapeutic Candidates Towards the Clinic
- 5 May 2021Portfolio NewsXilio Therapeutics Appoints Christina Rossi to its Board of Directors
- 26 April 2021Portfolio NewsCatamaran Bio Announces Appointment of Scott Holmes as Chief Financial Officer
- 20 April 2021Portfolio NewsMestag Therapeutics launches with seed financing of $11 million to develop therapeutics targeting activated fibroblast populations across inflammatory disease and cancer
- 15 April 2021Portfolio NewsAlchemab raises £60M ($82M) in Series A financing to advance novel platform for identifying disease-modifying antibody therapeutics